KDC-MN-1641 – Kodiac biolabs

Our opinion on this compoundNovel, promising

69/100

First-in-class cardiolipin-binding peptide with FDA approval for Barth syndrome and genuine bench probe utility

Look, the Szeto-Schiller peptide story is one of the more interesting accidents in mitochondrial pharmacology. SS-31 was discovered while chasing opioid receptors, and what came out was something genuinely different: a synthetic tetrapeptide that ignores cytoplasm almost entirely, concentrates more than 1000-fold in the inner mitochondrial membrane, and works not as a stoichiometric antioxidant but as an electrostatic modulator of cardiolipin-containing bilayers. The Mitchell et al. 2020 biophysical work nailed the mechanism with real precision: dissociation constant of 2.0 to 2.9 micromolar for cardiolipin membranes, saturable surface potential reduction, divalent cation exclusion operating independently of membrane potential. Thats not receptor hand-waving. That’s a physical chemistry description of how the compound actually works.

The FDA accelerated approval for Barth syndrome in September 2025 under the name FORZINITY is meaningful, and we should say so plainly. Barth syndrome patients carry tafazzin gene mutations that produce structurally defective cardiolipin, which is precisely the molecular substrate where elamipretide is most directly operative. The TAZPOWER open-label extension showed cumulative 96-meter improvement in six-minute walk distance at 168 weeks (P = 0.003) plus sustained knee extensor gains. Its not a massive effect size, but in a disease with no prior approved therapy and a mechanism this well-matched to the underlying pathology, it clears the bar. The ex vivo failing human heart work is equally compelling: at 100 micromolar, elamipretide selectively restored Complex I-driven oxygen flux and respiratory control ratio in failing tissue but not in non-failing controls, a disease-selective readout you can’t get from a generic antioxidant.

What we don’t love is the broader program. MMPOWER-3 (n = 218) missed its co-primary endpoints in primary mitochondrial myopathy. Heart failure with reduced ejection fraction trials, including PROGRESS-HF and EMBRACE-STEMI, similarly didn’t meet primary endpoints. The dry AMD ReCLAIM series added another failure. The pattern that emerges is a compound that’s exquisitely suited to populations with primary cardiolipin pathology and much weaker in heterogeneous mitochondrial dysfunction. The MMPOWER post hoc finding of a responding subgroup with nuclear DNA replisome variants and CPEO phenotype is genuinely worth following, but its not confirmatory.

For investigators, the bench probe value here is substantial and somewhat independent of the clinical story. Elamipretide is currently the only tool that lets you interrogate cardiolipin-ETC supercomplex interactions in live or freshly explanted tissue without membrane disruption. If your research program touches cardiolipin remodeling, cristae architecture, or supercomplex stability, this is the compound that makes previously unanswerable questions answerable. Pharmacokinetically it’s clean: 92 percent subcutaneous bioavailability, no hepatic metabolism, no CYP interactions, short half-life, predictable dosing profile for preclinical translation.

We place this solidly in the novel-promising tier. The mechanism is first-in-class, the Barth syndrome approval gives the cardiolipin story real regulatory weight, and the bench utility is high. But repeated broad-indication failures and an accelerated rather than full approval temper the translational score. The aging skeletal muscle and CPEO subgroup programs are worth watching closely as the next legible signal.

Novelty: 68
Mechanism promise: 78
In-category differentiation: 75
Evidence quality: 58
Translational signal: 62
Research bench value: 70

Rationale Elamipretide holds the first-in-class cardiolipin-binding mechanism with rigorous biophysical characterization and FDA accelerated approval in Barth syndrome, but a broad clinical program that repeatedly failed primary endpoints outside that genetically defined population keeps translational and evidence scores from climbing higher; bench probe value for cardiolipin-ETC supercomplex work is independently strong.

Mitochondria-targeted aromatic-cationic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane

A first-in-class cardiolipin-binding tetrapeptide developed by Szeto and Schiller that stabilizes mitochondrial cristae architecture, restores electron transport chain supercomplex function, and received FDA accelerated approval for Barth syndrome as the first mitochondria-targeted peptide therapeutic.

Abstract

Elamipretide (D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH2; also designated SS-31, MTP-131, and Bendavia) is a synthetic aromatic-cationic tetrapeptide that concentrates more than 1000-fold in the inner mitochondrial membrane, where it binds cardiolipin and modulates membrane surface electrostatics to stabilize cristae architecture, optimize electron transport chain supercomplex assembly, and reduce reactive oxygen species generation at the mitochondrial source. Discovered fortuitously by Hazel Szeto and Peter Schiller during opioid receptor research, the compound was characterized in a foundational 2004 report demonstrating nanomolar-range cytoprotection against oxidative cell death and reperfusion injury in isolated mitochondria and ex vivo cardiac tissue. Biophysical studies by Mitchell et al. (2020) have since established that the primary mechanism is not stoichiometric antioxidant scavenging but rather electrostatic modulation of anionic lipid bilayer properties: SS-31 partitions into the membrane interfacial region with a dissociation constant of 2.0 to 2.9 micromolar for cardiolipin-containing membranes, saturably reduces surface potential, and decreases interfacial divalent cation accumulation by over an order of magnitude; these effects are independent of mitochondrial membrane potential. In freshly explanted failing human heart tissue, elamipretide at 100 micromolar selectively restored Complex I-driven oxygen flux, supercomplex coupling, and respiratory control ratio without affecting non-failing hearts, confirming a disease-selective mechanism operating through cardiolipin-protein interaction stabilization rather than cardiolipin remodeling. Stealth BioTherapeutics advanced elamipretide through clinical programs in Barth syndrome (TAZPOWER), primary mitochondrial myopathy (MMPOWER series), heart failure with reduced ejection fraction (PROGRESS-HF, EMBRACE-STEMI), and dry age-related macular degeneration (ReCLAIM series). The Barth syndrome program, conducted in patients with tafazzin gene mutations and defective cardiolipin remodeling, demonstrated sustained improvements in six-minute walk distance (cumulative 96.1 meters at 168 weeks, P = 0.003) and knee extensor muscle strength in the open-label extension, leading to FDA accelerated approval in September 2025 under the brand name FORZINITY for improvement of muscle strength in adult and pediatric patients weighing at least 30 kilograms. The 12-week randomized crossover portion of TAZPOWER did not meet its primary endpoints, and the pivotal Phase 3 trial in primary mitochondrial myopathy (MMPOWER-3, n = 218) did not meet co-primary endpoints on six-minute walk test and fatigue score, though post hoc analysis identified a responding subgroup with nuclear DNA replisome pathogenic variants and chronic progressive external ophthalmoplegia phenotype. Heart failure and macular degeneration trials similarly did not meet primary endpoints, though exploratory signals in cardiac volume reduction and ellipsoid zone preservation were observed. Pharmacokinetically, elamipretide is administered as a 40 mg subcutaneous injection once daily, with absolute bioavailability of approximately 92 percent, time to peak concentration of 0.5 to 1 hour, plasma elimination half-life of approximately 3 to 4 hours, and exclusively renal elimination with no hepatic metabolism and no cytochrome P450 interactions. This monograph reviews the chemistry and structure, discovery history, cardiolipin-binding pharmacology, pharmacokinetics, preclinical evidence across cardiac, renal, neuroinflammatory, and aging models, the complete clinical trial inventory across all studied indications, sourcing and quality verification, handling, drug interactions, adverse event profile, and a comparative assessment of five mitochondrial therapeutics (idebenone, omaveloxolone, MitoQ, vatiquinone, and coenzyme Q10) against elamipretide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1641Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1641

Elamipretide

Abstract

Read the full monograph